“On August 2023, 8, CARsgen announced that it and Moderna have launched a collaboration agreement to study the combined therapeutic effects of CARsgen Pharmaceutical’s Claudin 21.18 CAR-T product candidate (CT2) with Moderna’s investigational Claudin 041.18 mRNA cancer vaccine.
CT041 (satricabtagene autoleucel) is an autologous CAR-T cell product of CARsgen Pharmaceutical, which is studying its potential for the treatment of gastric cancer, pancreatic cancer and other specific digestive tumors, and is currently conducting multiple clinical studies in China and North America…”

Continue reading at the original source, linked here.